FDA picks apart Brain­Stor­m's po­ten­tial ALS treat­ment ahead of Wednes­day ad­comm

The un­met need for pa­tients with the pro­gres­sive neu­rode­gen­er­a­tive dis­ease ALS, or amy­otroph­ic lat­er­al scle­ro­sis, is un­doubt­ed­ly high. But the FDA is draw­ing the line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.